



**Congress Presidents**  
Axel Hauschild, Kiel, Germany  
Claus Garbe, Tuebingen, Germany

**HYBRID  
EVENT**

# 13<sup>th</sup> European Post-Chicago Melanoma/Skin Cancer Meeting

## Interdisciplinary Global Conference on News in Melanoma/Skin Cancer

**Final Program**

**June 22<sup>nd</sup>–23<sup>rd</sup>, 2023**  
**Munich, Germany**  
**Hilton Hotel Munich Park**



Under the auspices of the  
European Association  
of Dermato-Oncology

# CONTENT

---

»» WELCOME MESSAGE 01

---

»» PROGRAM AT A GLANCE 02

---

»» PROGRAM 04

Thursday, June 22<sup>nd</sup>, 2023 04

Friday, June 23<sup>rd</sup>, 2023 07

---

»» CONGRESS FACULTY 10

---

»» SATELLITE SYMPOSIA OVERVIEW 14

---

»» FLOOR PLAN 16

---

»» GENERAL INFORMATION 18

---

»» SPONSORS 20

---

»» NOTES 32

---

# WELCOME MESSAGE

Dear colleagues and friends,

The first Post-Chicago Meeting on Melanoma/Skin Cancer took place 2011. In 2019, the meeting attracted **more than 700 participants**. **In 2022 the meeting was held as a hybrid meeting with more than 400 attendees on-site and another 500 virtually**. The interactive congress offers a comprehensive overview of all new developments in melanoma diagnostics and therapy and direct communication with the world's leading experts in these fields.

**The aim of the Interdisciplinary Global Conference on News in Melanoma/Skin Cancer in Munich is to grant a deep overall insight into the development of new drugs for melanoma and other cutaneous malignancies.** The lively interaction of clinicians, as well as experts in translational and basic research, and representatives of the pharmaceutical industry, guarantees a successful outcome for every participant.

International key opinion leaders on melanoma will be invited to give an overview throughout specified presentations, to present the latest clinical trial results, and to discuss exciting new drugs with the audience. In addition to the scientific value of this meeting, every participant may seize the given opportunity to interact with experts in a familiar setting in one of the most interesting cities in Germany.

**We welcome you in Munich and online!**



Axel Hauschild, MD  
Congress President



Claus Garbe, MD  
Congress President

# PROGRAM AT A GLANCE

## THURSDAY, JUNE 22<sup>nd</sup>, 2023

	BALLROOM*	RUMFORD
8:00	Opening of the conference <b>SYMPOSIUM I</b> My personal highlights at ASCO 2023	
9:00	<b>SATELLITE SYMPOSIUM I</b>	
10:00	<b>KEYNOTE LECTURE I</b>	
11:00	BREAK	
12:00	<b>SATELLITE SYMPOSIUM II</b>	
13:00	<b>SYMPOSIUM II</b> Controversies: Goodbye Sentinel Node Biopsy?	<b>PARALLEL SYMPOSIUM I</b> Adverse events of immune checkpoint inhibition
14:00	BREAK	
15:00	<b>SATELLITE SYMPOSIUM III</b>	
16:00	<b>SYMPOSIUM III</b> Adjuvant treatment: Parameters for selection of adjuvant treatment?	<b>EADO FORUM I</b> Interactive Case Discussions
17:00	BREAK	
18:00	<b>SYMPOSIUM IV</b> Neoadjuvant treatment: Ready for primetime?	<b>EADO FORUM II</b> Interactive Case Discussions
19:00	<b>SPECIAL LECTURE WITH DISCUSSION</b>	

\*All presentations in the BALLROOM will be broadcast live and will be available on demand after the event until September 30.

# FRIDAY, JUNE 23<sup>rd</sup>, 2023

	BALLROOM*	RUMFORD
8:00	<b>SYMPOSIUM V</b> Non Melanoma Skin Cancer: New Guidelines	<b>PARALLEL SYMPOSIUM II</b> Registries for melanoma and non-melanoma skin cancers
9:00		
10:00	<b>SATELLITE SYMPOSIUM IV</b>	
	<b>SATELLITE SYMPOSIUM V</b>	
11:00	BREAK	
	<b>KEYNOTE LECTURES II + III</b>	
12:00		
	<b>SATELLITE SYMPOSIUM VI</b>	
13:00		
	<b>SYMPOSIUM VI</b> Uveal Melanoma (unrestricted Educational Grant Immunocore)	
14:00		
	BREAK	
15:00	<b>KEYNOTE LECTURES IV + V</b>	
	<b>SATELLITE SYMPOSIUM VII</b>	
16:00	<b>SYMPOSIUM VII</b> New therapies under development	
17:00	<b>SPECIAL LECTURE WITH DISCUSSION</b>	
	<b>CLOSING REMARKS</b>	
18:00		
19:00		

# THURSDAY, JUNE 22<sup>nd</sup>, 2023

08:00

BALLROOM

## OPENING OF THE CONFERENCE

CHAIRPERSON: AXEL HAUSCHILD, KIEL, GERMANY

08:10–09:30

BALLROOM

## SYMPOSIUM I

My personal highlights at ASCO 2023

CHAIRPERSONS: LUCIE HEINZERLING, MUNICH, GERMANY  
MARKUS HEPPT, ERLANGEN, GERMANY

08:10–08:40 ... in melanoma

**Teresa Petrella, Toronto, Canada**

08:50–09:20 ... in non-melanoma skin cancer

**Dirk Schadendorf, Essen, Germany**

09:30–10:15

BALLROOM

## SATELLITE SYMPOSIUM I

*(see page 14)*

10:15–10:45

BALLROOM

## KEYNOTE LECTURE I

CHAIRPERSON: DIRK SCHADENDORF, ESSEN, GERMANY

10:15–10:45 Cell-based therapies for melanoma

**James Larkin, London, UK**

10:45–11:30

## BREAK

11:30–12:15

BALLROOM

## SATELLITE SYMPOSIUM II

*(see page 14)*

12:15–13:15

BALLROOM

## SYMPOSIUM II

Controversies: Goodbye Sentinel Node Biopsy?

CHAIRPERSONS: RALF GUTZMER, MINDEN, GERMANY  
PIOTR RUTKOWSKI, WARSAW, POLAND

12:15–12:35 Yes!

**Alexander Eggermont, Utrecht, The Netherlands**

12:35–12:55 No!

**Merrick I. Ross, Houston, USA**

12:55–13:15 Panel discussion

**Alexander Eggermont, Merrick Ross, Piotr Rutkowski**

# THURSDAY, JUNE 22<sup>nd</sup>, 2023

12:15–13:15

RUMFORD

## PARALLEL SYMPOSIUM I

Adverse events of immune checkpoint inhibition

CHAIRPERSONS: JESSICA HASSEL, HEIDELBERG, GERMANY  
TERESA PETRELLA, TORONTO, CANADA

12:15–12:30 Cardiac toxicities

**Teresa Petrella, Toronto, Canada**

12:30–12:45 Neurological adverse events

**Jessica Hassel, Heidelberg, Germany**

12:45–13:00 Rare and late toxicities

**Lucie Heinzerling, Munich, Germany**

13:00–13:15 Panel discussion

**Teresa Petrella, Lucie Heinzerling, Jessica Hassel**

13:15–14:15

## BREAK

14:15–15:15

BALLROOM

## SATELLITE SYMPOSIUM III

*(see page 14)*

15:15–16:15

BALLROOM

## SYMPOSIUM III

Adjuvant treatment: Parameters for selection of adjuvant treatment?

CHAIRPERSONS: HELEN GOGAS, ATHENS, GREECE  
SANJIV AGARWALA, PHILADELPHIA, USA

15:15–15:30 Number needed to treat

**Ana Arance, Barcelona, Spain**

15:30–15:45 Number needed to harm

**Caroline Robert, Paris, France**

15:45–16:00 Can biomarkers (gene expression profiling, ctDNA, etc) help?

**Christoffer Gebhardt, Hamburg, Germany**

16:00–16:15 Panel discussion

**Helen Gogas, Ana Arance, Sanjiv Agarwala,  
Caroline Robert, Christoffer Gebhardt**

15:15–16:15

RUMFORD

## EADO FORUM I

Interactive Case Discussions

CHAIRPERSONS: JESSICA HASSEL, HEIDELBERG, GERMANY  
RICARDO VIEIRA, COIMBRA, PORTUGAL

15:15–15:25 Case 1 – **Josep Malvehy, Barcelona, Spain**

15:30–15:40 Case 2 – **Mirjana Ziemer, Leipzig, Germany**

15:45–15:55 Case 3 – **Ricardo Vieira, Coimbra, Portugal**

16:00–16:10 Case 4 – **Markus Heppt, Erlangen, Germany**

# THURSDAY, JUNE 22<sup>nd</sup>, 2023

16:15–16:30

BREAK

16:30–17:30

BALLROOM

## SYMPOSIUM IV

Neoadjuvant treatment: Ready for primetime?

CHAIRPERSONS: CHRISTOFFER GEBHARDT, HAMBURG, GERMANY  
PAOLO ASCIERTO, NAPLES, ITALY

16:30–16:50 Combination: Neoadjuvant + adjuvant immune  
checkpoint inhibition  
**Sapna Patel, Houston, USA**

16:50–17:10 Just neoadjuvant without adjuvant immune  
checkpoint inhibition  
**James Larkin, London, UK**

17:10–17:30 Panel Discussion  
**Paolo Ascierto, James Larkin,  
Christoffer Gebhardt, Sapna Patel**

16:30–17:30

RUMFORD

## EADO FORUM II

Interactive Case Discussions

CHAIRPERSONS: PETR ARENBERGER, PRAGUE, CZECH REPUBLIC  
RODRIGO MUNHOZ, SAO PAULO, BRAZIL

16:30–16:40 Case 5 – **Zeljko Mijuskovic, Belgrade, Serbia**

16:45–16:55 Case 6 – **Chalid Assaf, Krefeld, Germany**

17:00–17:10 Case 7 – **Petr Arenberger, Prague, Czech Republic**

17:15–17:25 Case 8 – **Rodrigo Munhoz, Sao Paulo, Brazil**

17:30–18:30

BALLROOM

## SPECIAL LECTURE WITH DISCUSSION

CHAIRPERSON: ALEXANDER EGGERMONT, UTRECHT,  
THE NETHERLANDS

17:30–18:00 The future of intralesional treatments  
**Christoph Höller, Vienna, Austria**

18:00–18:30 Panel Discussion  
**James Larkin, Alexander Eggermont,  
Christoph Höller, Merrick I. Ross**

# FRIDAY, JUNE 23<sup>rd</sup>, 2023

08:00–10:00

BALLROOM

## SYMPOSIUM V

### Non Melanoma Skin Cancer: New Guidelines

CHAIRPERSONS: RODRIGO MUNHOZ, SAO PAULO, BRAZIL  
ROLAND KAUFMANN, FRANKFURT, GERMANY

08:00–08:20 Actinic keratoses

**Lidija Kandolf, Belgrade, Serbia**

08:25–08:45 Cutaneous squamous cell carcinoma

**Rodrigo Munhoz, Sao Paulo, Brazil**

08:50–09:10 Basal cell carcinoma

**Roland Kaufmann, Frankfurt, Germany**

09:15–09:35 Merkel cell carcinoma

**Celeste Lebbe, Paris, France**

09:40–10:00 Rare tumors (DFSP, AFX, DPS, Angiosarcoma):  
Interdisciplinary Guideline

**Selma Ugurel, Essen, Germany**

08:00–10:00

RUMFORD

## PARALLEL SYMPOSIUM II

### Registries for melanoma and non-melanoma skin cancers

CHAIRPERSONS: LIDIJA KANDOLF, BELGRADE, SERBIA  
MICHAEL WEICHENTHAL, KIEL, GERMANY  
PETER MOHR, BUXTEHUDE, GERMANY

08:00–08:10 Introduction Registries for real world evidence

**Peter Mohr, Buxtehude Germany**

08:10–08:25 MelaBase registry structure, current development and  
future projects

**Celeste Lebbe, Paris, France**

08:30–08:45 ADOREG – current development and latest  
results of the German registry

**Ralf Gutzmer, Minden, Germany**

08:50–09:05 Melanoma registries in Spain

**Josep Malvehy, Barcelona, Spain**

09:10–09:25 Side Effect Registry Immuno-Oncology (SERIO) registry

**Lucie Heinzerling, Erlangen, Germany**

09:30–09:45 European non-melanoma skin cancer  
registries – challenges and European perspective

**Lidija Kandolf, Belgrade, Serbia**

09:50–10:05 The EUMelaReg treatment registry: structure and first results

**Michael Weichenthal, Kiel, Germany**

10:10–10:30 Panel discussion

**All**

# FRIDAY, JUNE 23<sup>rd</sup>, 2023

10:00–10:30

BALLROOM

SATELLITE SYMPOSIUM IV  
*(see page 15)*

10:30–11:00

BALLROOM

SATELLITE SYMPOSIUM V  
*(see page 15)*

11:00–11:30

BREAK

11:30–12:30

BALLROOM

KEYNOTE LECTURES II + III

CHAIRPERSONS: ROLAND KAUFMANN, FRANKFURT, GERMANY  
CHRISTOFFER GEBHARDT, HAMBURG, GERMANY

11:30–12:00 How to sequence melanoma drugs intelligently?  
**Paolo Ascierto, Naples, Italy**

12:00–12:30 How to improve immune checkpoint inhibitor treatment?  
**James Larkin, London, UK**

12:30 - 13:30

BALLROOM

SATELLITE SYMPOSIUM VI  
*(see page 15)*

13:30–14:15

BALLROOM

SYMPOSIUM VI

Uveal Melanoma (unrestricted Educational Grant Immunocore)

CHAIRPERSON: AXEL HAUSCHILD, KIEL, GERMANY

13:30–13:45 Clinical features and treatment of ocular melanomas  
**Nikolaos Bechrakis, Essen, Germany**

13:45–14:00 Tebentafusp updated clinical trial results in  
metastatic uveal melanoma  
**Heather Shaw, London, UK**

14:00–14:15 Adverse management: tips and tricks  
**Jessica Hassel, Heidelberg, Germany**

14:15–14:50

BREAK

# FRIDAY, JUNE 23<sup>rd</sup>, 2023

14:50–15:30

BALLROOM

## KEYNOTE LECTURES IV + V

CHAIRPERSON: AXEL HAUSCHILD, KIEL, GERMANY

14:50–15:10 Resistance mechanisms of targeted therapies  
**Olivier Michielin, Geneva, Switzerland**

15:10–15:30 The role of personalized vaccines for skin cancer  
**Jeffrey Weber, New York, USA**

15:30–16:00

BALLROOM

## SATELLITE SYMPOSIUM VII

*(see page 15)*

16:00–17:00

BALLROOM

## SYMPOSIUM VII

New therapies under development

CHAIRPERSONS: DIRK SCHADENDORF, ESSEN, GERMANY  
OLIVIER MICHIELIN, GENÈVE, SWITZERLAND

16:00–16:17 Immunotherapies  
**Christoffer Gebhardt, Hamburg, Germany**

16:20–16:37 Vaccination  
**Reinhard Dummer, Zurich, Switzerland**

16:40–16:57 Targeted therapies  
**Ralf Gutzmer, Minden, Germany**

17:00–17:35

BALLROOM

## SPECIAL LECTURE WITH DISCUSSION

CHAIRPERSONS: SAPNA PATEL, HOUSTON, USA  
CAROLA BERKING, ERLANGEN, GERMANY

17:00–17:20 Treatment or no treatment at the end of the life?  
**Andrea Forschner, Tuebingen, Germany**

17:20–17:35 Panel Discussion  
**Carola Berking, Andrea Forschner, Sapna Patel**

17:40

BALLROOM

## CLOSING REMARKS

**Claus Garbe, Tuebingen, Germany**

# CONGRESS FACULTY

## A

---

**Alexander van Akkooi, MD**

Melanoma Institute Australia  
Cammeraygal LandThe Poche Centre 40  
Rocklands Road Wollstonecraft NSW 2065, Australia

**Ana Arance, MD**

Hospital Clínic de Barcelona  
Universitat de Barcelona  
C. Villarroel, 170  
08036 Barcelona, Spain

**Sanjiv Agarwala, MD**

Professor, Temple University School of Medicine  
3500 N Broad St, Philadelphia  
PA 19140, United States

**Petr Arenberger, MD**

Professor of Dermatology,  
Director Department of Dermatology  
Charles University  
3rd School of Medicine  
Prague, Czech Republic

**Paolo Ascierto, MD**

Melanoma, Cancer Immunotherapy and  
Innovative Therapy Unit National Cancer Institute  
Naples, Italy

## B

---

**Nikolaos Bechrakis, MD**

Department of Ophthalmology  
Universitätsklinikum Essen  
Essen, Germany

**Carola Berking, MD**

Department of Dermatology  
University Hospital of Erlangen  
Erlangen, Germany

## C

---

**Antonio Cozzio, MD**

Cantonal Hospital St.Gallen  
Clinic for Dermatology, Venereology and Allergology  
Rorschacher Strasse 95  
St.Gallen, Switzerland

## D

---

**Reinhard Dummer, MD**

Department of Dermatology University of Zurich  
Zurich, Switzerland

## E

---

**Alexander Eggermont, MD**

University of Utrecht  
Utrecht, The Netherlands  
Princess Maxima Center  
Heidelberglaan 25  
3584 CS Utrecht, The Netherlands

## F

---

**Andrea Forschner, MD**

Department of Dermatology  
Eberhard Karls University  
Tuebingen, Germany

## G

---

### **Claus Garbe, MD**

Department of Dermatology  
Eberhard Karls University  
Tuebingen, Germany

### **Christoffer Gebhardt, MD**

Skin Cancer Center  
University Hospital Hamburg-Eppendorf  
Hamburg, Germany

### **Helen Gogas, MD**

Professor in Medical Oncology  
First Department of Medicine  
National and Kapodistrian University  
Athens, Greece

### **Ralf Gutzmer, MD**

Department of Dermatology  
Johannes Wesling Medical Center Minden  
Ruhr University Bochum Campus Minden, Germany

## H

---

### **Jessica Hassel, MD**

Universitätsklinikum Heidelberg  
Heidelberg, Germany  
Universitätsklinikum Heidelberg  
Im Neuenheimer Feld 460  
69120 Heidelberg, Germany

### **Axel Hauschild, MD**

Professor of Dermatology  
Department of Dermatology  
University of Kiel  
Kiel, Germany

### **Lucie Heinzerling, MD, MPH**

Department of Dermatology University  
Hospital of Munich  
Munich, Germany

### **Markus Heppt, MD**

Department of Dermatology  
University Hospital of Erlangen  
Erlangen, Germany

### **Christoph Höller, MD**

Department of Dermatology  
Medical University of Vienna  
Vienna, Austria

## K

---

### **Lidija Kandolf, MD**

Professor of Dermatology  
Department of Dermatology  
Medical Faculty  
Military Medical Academy  
Belgrade, Serbia

### **Roland Kaufmann, MD**

Department of Dermatology  
Clinical Center J. W. Goethe University  
Frankfurt am Main, Germany

## L

---

### **James Larkin, MD**

The Royal Marsden/Institute of Cancer Research NIHR  
Biomedical Research Centre  
Fulham Road  
London SW3 6JJ, United Kingdom

### **Celeste Lebbe, MD**

Professor of Dermatology  
Department of Dermatology  
Hôpital Saint-Louis  
Paris, France

# CONGRESS FACULTY

## M

---

**Mario Mandala, MD**

University of Perugia  
Piazza dell'Università, 1  
06123 Perugia, Italy

**Josep Malvehy, MD**

Director of the Melanoma Unit  
Department of Dermatology  
Hospital Clinic of Barcelona  
Barcelona, Spain

**Olivier Michielin, MD**

Department of Oncology  
University Hospitals of Geneva  
Geneva, Switzerland

**Zeljko Mijuskovic, MD**

Professor of Dermatology  
Department of Dermatology  
Medical Faculty  
Military Medical Academy  
Belgrade, Serbia

**Peter Mohr, MD**

Chief Physician  
Department of Dermatology  
Elbe Klinikum Buxtehude  
Head of Skin Cancer Center Buxtehude  
Buxtehude, Germany

**Rodrigo Munhoz, MD**

Hospital Sírio Libanês  
Instituto do Câncer do Estado de São Paulo  
São Paulo, Brazil

## P

---

**Sapna Patel, MD**

MD Anderson Cancer Centre  
1515 Holcombe Blvd.  
Houston, Texas 77030, United States

**Teresa Petrella, MD**

Medical Director, Sunnybrook Odette  
Cancer Centre Clinical Trials  
Toronto, Canada

## R

---

**Caroline Robert, MD**

Gustave Roussy Institute  
Villejuif/Paris, France

**Merrick I. Ross, MD**

MD Anderson Cancer Centre  
1515 Holcombe Blvd.  
Houston, Texas 77030, United States

**Piotr Rutkowski, MD**

Maria Sklodowska-Curie National  
Research Institute of Oncology  
Warsaw, Poland

## S

---

**Dirk Schadendorf, MD**

Department of Dermatology  
University Hospital Essen  
Essen, Germany

**Heather Shaw, MD**

University College London Hospital and Mount Vernon  
Cancer Centre  
Huntley St, London WC1E 6AG, United Kingdom

## U

---

**Selma Ugurel, MD**

Department of Dermatology  
University Hospital Essen  
Essen, Germany

## V

---

**Ricardo Vieira, MD**

Faculty of Medicine  
University of Coimbra  
Coimbra, Portugal

## W

---

**Jeffrey Weber, MD**

Laura and Isaac Perlmutter Cancer Center  
A NCI-funded Comprehensive Cancer Center  
522 First Avenue  
Room 1310 Smilow Building  
New York, NY 10016

**Michael Weichenthal, MD**

Professor of Dermatology  
Department of Dermatology  
University of Kiel  
Kiel, Germany

## Z

---

**Mirjana Ziemer, MD**

Skin Cancer Centre Leipzig  
University Hospital Leipzig  
Philipp-Rosenthal-Straße 23, Haus 10  
04103 Leipzig, Germany

# SATELLITE SYMPOSIA OVERVIEW

THURSDAY, JUNE 22<sup>nd</sup>, 2023

09:30–10:15 SATELLITE SYMPOSIUM I

**BMS** Gold Sponsor

**Thoughts on innovation in melanoma – discussion and outlook**

Panel discussion with Prof. Dr. Christoph Hoeller (Vienna),  
PD Dr. Mirjana Ziemer (Leipzig) and Prof. Dr. Axel Hauschild (Kiel),  
who will also moderate the event.

The audience is invited to participate in the discussion with their own questions.

11:30–12:15 SATELLITE SYMPOSIUM II

**PIERRE FABRE** Gold Sponsor

**Breaking barriers: Multidisciplinary approaches in the management of BRAF-mutant melanoma patients**

CHAIRPERSON: CÉLESTE LEBBÉ

11:30–11:35 Welcome and introduction

**Céleste Lebbé**

11:35–11:55 Panel perspectives: Optimising management of patients with advanced BRAF-mutant melanoma

**Céleste Lebbé, Jessica Hassel, Alexander van Akkooi**

11:55–12:10 Unveiling present and future treatment strategies for early stage BRAF-mutant melanoma

**Alexander van Akkooi**

12:10–12:15 Audience Q&A and closing remarks

**All faculty (moderated by Céleste Lebbé)**

14:15–15:15 SATELLITE SYMPOSIUM III

**SANOFI REGENERON** Platinum Sponsor

**Evolving Therapeutic Landscape for Non-melanoma Skin Cancer**

14:15–14:17 Welcome and Introduction

**Dirk Schadendorf, Essen, Germany**

14:17–14:29 Update on Treatment Strategies in Advanced Non-melanoma Skin Cancer

**Dirk Schadendorf, Essen, Germany**

14:29–14:41 Evolution of Management and Guidelines for High-risk Cutaneous Squamous Cell Carcinoma

**Heather Shaw, London, United Kingdom**

14:41–14:46 Panel Discussion

**All Faculty, Moderated by Chair**

14:46–14:58 Application for Immunotherapy in Immunosuppressed Patients in Clinical Practice

**Celeste Lebbe, Paris, France**

14:58–15:10 Cutaneous Squamous Cell Carcinoma as a Model for Neoadjuvant Immunotherapy

**Mario Mandala, Perugia, Italy**

15:10–15:15 Panel Discussion

**All Faculty, Moderated by Chair**

## FRIDAY, JUNE 23<sup>rd</sup>, 2023

---

### 10:00–10:30 SATELLITE SYMPOSIUM IV

#### **KYOWA KIRIN BRONZE** Sponsor

10:00–10:24 Mogamulizumab: Mode of action and clinical perspectives in cutaneous lymphomas  
**Reinhard Dummer, Zurich, Switzerland**

10:24–10:30 Closing Discussion

---

### 10:30–11:00 SATELLITE SYMPOSIUM V

#### **PHILOGEN** Bronze Sponsor

#### **Advances in the treatment of high-risk BCC patients**

CHAIRPERSONS: AXEL HAUSCHILD, KIEL, GERMANY  
CLAUS GARBE, TUEBINGEN, GERMANY

Immunotherapy Advances in the Management of NMSC  
**Antonio Cozzio, St. Gallen, Switzerland**

---

### 12:30–13:30 SATELLITE SYMPOSIUM VI

#### **MSD** Platinum Sponsor

#### **Evolving clinical landscape in melanoma: How do we treat in 2023?**

CHAIRPERSON: AXEL HAUSCHILD, KIEL, GERMANY

12:30–12:35 Welcome and introduction

**Axel Hauschild, Kiel, Germany**

12:35–12:50 Recent advances in resected high-risk melanoma

**Axel Hauschild, Kiel, Germany**

12:50–13:05 Advanced melanoma treatment: A personalized care approach

**Peter Mohr, Buxtehude, Germany**

13:05–13:25 Case-based presentation and panel discussion

**Merrick Ross, Houston, Texas**

13:25–13:30 Closing remarks

**Axel Hauschild, Kiel, Germany**

---

### 15:30–16:00 SATELLITE SYMPOSIUM VII

#### **REPLIMUNE** Bronze Sponsor

#### **RP1: a new oncolytic virus approach on all skin cancers?**

First results on RP1 in metastatic melanoma

**Caroline Robert, Villejuif, France**


First results on RP1 in non-melanoma skin cancer

**Axel Hauschild, Kiel, Germany**


# FLOOR PLAN

## HILTON MUNICH PARK


### ERDGESCHOSS/GROUND FLOOR



### MEZZANINE



# FOYER BALLROOM



# GENERAL INFORMATION

## Cancellation Policy

Cancellations must be received in writing by May 11<sup>th</sup>, 2023. No refunds will be granted after that date. To cancel a registration, please send an email to [info@medconcept.org](mailto:info@medconcept.org) and include "European Post-Chicago Meeting 2023 Cancellation" in the subject line. A processing fee of 30 euros will be deducted from each canceled registration.

Substitutions (new ticket holders must come from the same institution) are possible and must be received in writing by June 16<sup>th</sup>, 2023. To substitute a registration please send an email including the name of the original registrant and the name of the person substituting to [info@medconcept.org](mailto:info@medconcept.org) and include "European Post-Chicago Meeting 2023 Substitution" in the subject line.

The participant acknowledges that he/she has no right to lodge damage claims against the organizers should the holding of the meeting be hindered or prevented by unexpected, political or economic events or generally by force or should the non-appearance of speakers or other reasons need program changes. With registration, the participant accepts this proviso.

## CME Credits

The **13th European Post-Chicago Meeting 2023, Munich, Germany, 22/06/2023–23/06/2023** has been accredited by the European Accreditation Council for Continuing Medical Education (EACCME®) with 10 European CME credits (ECMEC®s). Each medical specialist should claim only those hours of credit that he/she actually spent in the educational activity.

Through an agreement between the Union Européenne des Médecins Spécialistes and the American Medical Association, physicians may convert EACCME® credits to an equivalent number of AMA PRA Category 1 Credits™. Information on the process to convert EACCME® credit to AMA credit can be found at [www.ama-assn.org/education/earn-credit-participation-international-activities](http://www.ama-assn.org/education/earn-credit-participation-international-activities).

Live educational activities, occurring outside of Canada, recognized by the UEMS-EACCME® for ECMEC®s are deemed to be Accredited Group Learning Activities (Section 1) as defined by the Maintenance of Certification Program of the Royal College of Physicians and Surgeons of Canada.

## How to receive your CME Credits

To receive your daily CME credits please scan yourself once a day at the registration desk. German participants must also register in the barcode list of the Bavarian Medical Association. To obtain the CME certificate, the official EACCME questionnaire must be filled out online. The link to the survey will be sent within 10 days after the congress.

## Congress Date

June 22<sup>nd</sup>–June 23<sup>rd</sup>, 2023

## Congress Organization



Gesellschaft für medizinische Projekte mbH  
Friedenstraße 58, 15366 Neuenhagen bei Berlin, Germany  
[info@medconcept.org](mailto:info@medconcept.org)  
[www.medconcept.org](http://www.medconcept.org)  
Phone +49 (0)3342 42689-30  
Fax +49 (0)3342 42689-40

## Congress Venue

HILTON MUNICH PARK, Am Tucherpark 7, 80538 Munich, Germany  
Phone: +49 (0)89 3845 0  
Fax: +49 (0)89 3845 2588  
E-Mail: info.munich@hilton.com  
www.munich-park.hilton.com

## Exhibition

A commercial exhibition will be held at the congress venue, close to the main rooms.

### Exhibition Opening Hours

Thursday, June 22<sup>nd</sup>, 2023 07:30–18:30  
Friday, June 23<sup>rd</sup>, 2023 07:30–18:00

## Insurance

The Organizer does not accept liability for individual medical, travel or personal insurance and participants are strongly advised to make their own arrangements with respect to health and travel insurance.

## Language and Translation

The official language of the meeting will be English. Simultaneous translation will not be provided.

## Registration and Information Desk

The registration desk is situated at the ground floor of the Hilton Hotel to the right of the reception and in front of the meeting area entrance.

### Registration Desk Opening Hours

Wednesday, June 21<sup>st</sup>, 2023 16:00–18:00 (early check-in)  
Thursday, June 22<sup>nd</sup>, 2023 07:00–19:00  
Friday, June 23<sup>rd</sup>, 2023 07:30–18:00

## Registration Fees

Virtual packages and on-demand service is included in all ticket categories.

	Presence Tickets			Virtual Tickets
	Early Bird until May 1 <sup>st</sup> , 2023	Regular Fee until June 16 <sup>th</sup> , 2023	Late	
Full Delegate Ticket	400 euros	500 euros	600 euros	400 euros
EADO Members	300 euros	400 euros	500 euros	300 euros
Students/Nurses Ticket*	150 euros	200 euros	250 euros	150 euros
Eastern European Countries*	150 euros	200 euros	250 euros	150 euros
Residents*	150 euros	200 euros	250 euros	150 euros

\*Please upload proof of university or clinic for students/nurse ticket, and proof of residence in a european eastern country for reduced tickets of this category, during registration process.

# SPONSORS

## PLATINUM



sanofi *REGENERON*

## GOLD



## SILVER

IMMUNOCORE



## BRONZE



## EXHIBITORS

agenus



Philogen  
innovating targeting



Platinum: 120,000 Euros / Gold: 90,000 Euros / Silver: 60,000 Euros / Bronze: 35,000 Euros

# Evolving Therapeutic Landscape for Non-melanoma Skin Cancer

Thursday, 22 June 2023 | 14:15–15:15 CEST

Ballroom, Hilton Hotel Munich Park,  
Munich, Germany



**Prof. Dirk Schadendorf**

University Hospital Essen,  
Essen, Germany



**Dr Heather Shaw**

University College  
London Hospital,  
London, United Kingdom



**Prof. Céleste Lebbe**

Saint Louis  
University Hospital,  
Paris, France



**Prof. Mario Mandala**

University of Perugia,  
Perugia, Italy

**14:15 – 14:17**

## **Welcome and Introduction**

Prof. Dirk Schadendorf (Germany), Chair

**14:17 – 14:29**

## **Update on Treatment Strategies in Advanced Non-melanoma Skin Cancer**

Prof. Dirk Schadendorf (Germany)

**14:29 – 14:41**

## **Evolution of Management and Guidelines for High-risk Cutaneous Squamous Cell Carcinoma**

Dr Heather Shaw (United Kingdom)

**14:41 – 14:46**

## **Panel Discussion**

All Faculty, Moderated by Chair

**14:46 – 14:58**

## **Application for Immunotherapy in Immunosuppressed Patients in Clinical Practice**

Prof. Céleste Lebbe (France)

**14:58 – 15:10**

## **Cutaneous Squamous Cell Carcinoma as a Model for Neoadjuvant Immunotherapy**

Prof. Mario Mandala (Italy)

**15:10 – 15:15**

## **Panel Discussion**

All Faculty, Moderated by Chair

This symposium is intended for healthcare professionals only.

This industry-sponsored satellite symposium is organized and sponsored by Sanofi and Regeneron on the occasion of the 13<sup>th</sup> European Post-Chicago Melanoma/Skin Cancer Meeting | Munich, Germany, held 22–23 June 2023. This is not a CME program. This nonpromotional event sponsored by Sanofi and Regeneron will include discussion of investigational products and products that may not be approved by the regulatory agency in your own country.

MAT-GLB-2302689-V1.0; Date of approval: June 2023

**sanofi**

**REGENERON**

# Evolving clinical landscape in melanoma: How do we treat in 2023?

Hilton Hotel Munich Park  
Munich, Germany

**Friday, 23 June 2023**

12:30 – 13:30 (CEST)

Congress symposium sponsored by MSD

## Chair



**Axel Hauschild**

Professor and Head  
Dermato-Oncology  
Department  
University of Kiel  
Kiel, Germany

## Faculty



**Peter Mohr**

Chief Physician  
Department of Dermatology  
Elbe Klinikum Buxtehude  
Head of Skin Cancer  
Center Buxtehude  
Buxtehude, Germany



**Merrick Ross**

Professor of Surgery  
Chief, Melanoma Section  
Department of Surgical Oncology  
University of Texas  
MD Anderson Cancer Center  
Houston, Texas, USA

**Chair:** Axel Hauschild (Germany)

## Agenda

12:30 – 12:35	Welcome and introduction <b>Axel Hauschild</b>
12:35 – 12:50	Recent advances in resected high-risk melanoma <b>Axel Hauschild</b>
12:50 – 13:05	Advanced melanoma treatment: A personalized care approach <b>Peter Mohr</b>
13:05 – 13:25	Case-based presentation and panel discussion <b>Merrick Ross</b>
13:25 – 13:30	Closing remarks <b>Axel Hauschild</b>

## SATELLITE SYMPOSIUM

# Breaking barriers: Multidisciplinary approaches in the management of *BRAF*-mutant melanoma patients

Thursday, 22 June 2023, 11:30–12:15 CEST

Hilton Hotel Munich Park Munich, Germany  
Ballroom and live-streaming

### MEET THE EXPERTS



**Chair: Prof. Céleste Lebbé**  
Paris, France



**Prof. Alexander van Akkooi**  
Sydney, Australia



**Prof. Jessica Hassel**  
Heidelberg, Germany

### Agenda

11:30–11:35

**Welcome and introduction**

*Céleste Lebbé*

11:35–11:55

**Panel perspectives: Optimising management of patients with advanced *BRAF*-mutant melanoma**

*Céleste Lebbé, Jessica Hassel, Alexander van Akkooi*

11:55–12:10

**Unveiling present and future treatment strategies for early stage *BRAF*-mutant melanoma**

*Alexander van Akkooi*

12:10–12:15

**Audience Q&A and closing remarks**

*All faculty (moderated by Céleste Lebbé)*



# Extend efficacy in the adjuvant setting<sup>\*,1,2</sup>

**OPDIVO**<sup>®</sup>  
(nivolumab)



The only therapy indicated in the adjuvant setting for all patients with stage III and stage IV NED melanoma<sup>#, 1,3-6</sup>



OPDIVO<sup>®</sup> as monotherapy is indicated for the adjuvant treatment of adults with melanoma with involvement of lymph nodes or metastatic disease who have undergone complete resection.



**Scan here!**  
Summary of OPDIVO<sup>®</sup> Product Characteristics

NED = no evidence of disease \* RFS at 5 years.<sup>2</sup> # Checkmate 238 included stage IIIB/C and stage IV NED patients per AJCC 7th edition.<sup>2</sup>

1. OPDIVO<sup>®</sup> [package insert]. Princeton, NJ: Bristol-Myers Squibb Company. 2. Weber J, Larkin J, Mandalá M, et al. Five-year outcomes with adjuvant nivolumab versus ipilimumab in resected stage IIIB-C or IV melanoma (CheckMate 238). Oral presentation at the Society for Melanoma Research (SMR); October 28-31, 2021; Virtual Meeting. 3. TAFINLAR<sup>®</sup> [package insert]. East Hanover, NJ: Novartis Pharmaceuticals Corporation. 4. MEKINIST<sup>®</sup> [package insert]. East Hanover, NJ: Novartis Pharmaceuticals Corporation. 5. YERVOY<sup>®</sup> [package insert]. Princeton, NJ: Bristol-Myers Squibb Company. 6. KEYTRUDA<sup>®</sup> [package insert]. Whitehouse Station, NJ: Merck & Co Inc.

This material has been produced to ensure compliance with the EFPIA and local German regulations. The indications in this material are listed according to the European Commission licensing. Prescribing information may vary depending on local approval in each country or region. Therefore, before prescribing any product, always refer to local materials such as the prescribing information and/or the Summary of Product Characteristics (SPC).

©2021 Bristol-Myers Squibb Company. All rights reserved. OPDIVO<sup>®</sup>, YERVOY<sup>®</sup> and the related logos are trademarks of Bristol-Myers Squibb Company. 1506-DE-2300085 05/2023



## TAFINLAR® + MEKINIST® – FOR THE JOURNEY AHEAD

For more information on TAFINLAR® + MEKINIST®,  
please visit [www.tafmek.com](http://www.tafmek.com).

 **NOVARTIS**

Novartis Pharma AG ©2021 Novartis 12/21  
CH-4002 Basel Switzerland 108237

## Data-Driven Oncology

Empowering biopharmaceutical innovation with  
comprehensive, real-world data-driven insights

### Our Services

- Study design (Protocols, electronic case report forms (eCRFs), questionnaires, surveys)
- Definition of centers for recruitment and management
- Medical-scientific consulting
- Comprehensive study management
- Handling of regulatory submissions and approval processes
- IT infrastructure (electronic data capture, database services)
- Data collection and management
- Planning of biostatistical analyses and biostatistical evaluation
- Final reports, publications, medical writing
- Adverse event (AE)/Serious adverse event (SAE)/Adverse drug reaction (ADR)/Serious adverse drug reaction (SADR) management



Friedenstraße 58  
15366 Neuenhagen bei Berlin

Telefon: +49 (0) 3342 42689-50  
Fax: +49 (0) 3342 42689-60  
info@heraclin.de  
[www.heraclin.de](http://www.heraclin.de)



### Course Directors

Véronique Del Marmol, Brussels, Belgium  
Claus Garbe, Tuebingen, Germany  
Axel Hauschild, Kiel, Germany  
Giovanni Pellacani, Modena, Italy

# 12<sup>th</sup> EUROPEAN SCHOOL OF DERMATO-ONCOLOGY - UPDATE ON CUTANEOUS ONCOLOGY (ESDO) JANUARY 12<sup>th</sup>-13<sup>th</sup>, 2024 NOVOTEL BERLIN AM TIERGARTEN BERLIN, GERMANY



Apply now for EADO Certification 2024

# EADO Certification: Medical Tumour Therapy in Dermato-Oncology

**January 13, 2024**

Novotel Hotel am Tiergarten  
Berlin, Germany

**EADO.ORG**



Arbeitsgemeinschaft  
Dermatologische Onkologie  
**ADO**

**Dermato-Onkologie  
UPDATE 2024**

**23.-25.2.2024**  
im Novotel Berlin am Tiergarten  
HYBRID MEETING

**SAVE  
THE  
DATE**

# 20<sup>TH</sup>

## EADO CONGRESS

April 4<sup>th</sup>–6<sup>th</sup>, 2024

PARIS, FRANCE

PALAIS DES CONGRÈS VERSAILLES



**ABSTRACT SUBMISSION DEADLINE**  
FEBRUARY 15, 2024

ON-SITE CONGRESS WITH  
ADDITIONAL VIRTUAL ACCESS  
[WWW.EADO2024.COM](http://WWW.EADO2024.COM)

**3.-5.  
APRIL  
2025**

**11<sup>TH</sup> WORLD CONGRESS  
OF MELANOMA AND  
21<sup>ST</sup> EADO CONGRESS**

**Megaron Athens  
International Conference  
Centre  
Athens, Greece**



**Melanoma  
World Society  
MWS**

**SAVE  
THE  
DATE**



**worldmelanoma2025.com**

# Together into the future

Plan with us your next  
scientific event



MedConcept Gesellschaft  
für medizinische Projekte mbH  
Friedenstraße 58, 15366 Neuenhagen



+49 3342 42689-30



info@medconcept.org



www.medconcept.org

**MEDCONCEPT**   
Experience since 1997

# Congress On-Demand

**All sessions from the BALLROOM will be available on the On-Demand platform 48 hours after the session until September 30, 2023.**

The on-demand service is available to all registered attendees (F2F and virtual).

**THE AREA  
IS PASSWORD  
PROTECTED**



Access to the On-Demand area is granted using the same login credentials as for the virtual platform.









## IMPORTANT INFORMATION

### Internet Connection

Free Wi-Fi service will be available to all delegates within the Hilton Hotel Munich Park.

**Network Name: Post-Chicago Meeting**

**Network password: Munich2023**

### Certificate of Attendance:

All registered attendees will receive a certificate of attendance within 10 days after the meeting via e-mail and after completing an evaluation survey.

**Please note!** If you need to change your contact e-mail address, please come to the registration desk.

### Name Badges

Name badges must be worn visibly at all times during the meeting and in the exhibition area.

### Daily Scan

To receive your daily CME credits please remember to scan yourself once a day at the registration desk.

German participants must also register in the barcode list of the Bavarian Medical Association.

### TED/Polling

Please scan the QR code with your mobile device or visit **www.slido.com** and enter the event code to participate in the polling.

**BALLROOM**



event code  
#PC23Plenary

**RUMFORD**



event code  
#PC23Parallel

SAVE  
THE  
DATE

**June 27<sup>th</sup>–28<sup>th</sup>, 2024**  
HILTON HOTEL MUNICH PARK

**14<sup>th</sup> European Post-Chicago  
Melanoma/Skin Cancer Meeting**